Displaying drugs 1501 - 1525 of 2084 in total
Nivatrotamab
Nivatrotamab is under investigation in clinical trial NCT03860207 (Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3f8-bsab) in Patients With Relapsed/refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers).
Investigational
7,8-dihydroinosine
Experimental
Lumichrome
Experimental
Lumiflavin
Experimental
Etybenzatropine
Experimental
Matched Iupac: … (1R,3S,5S)-3-(diphenylmethoxy)-8-ethyl-8-azabicyclo[3.2.1]octane …
Tyrphostin AG 835
Experimental
Tropatepine
Tropatepine has been used in France for its antiparkinsons activities .
Experimental
Matched Iupac: … (1R,5S)-8-methyl-3-{9-thiatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3(8),4,6,11,13-hexaen-2-ylidene}-8-azabicyclo …
Cyclo(his-pro)
Experimental
Batefenterol
Batefenterol has been used in trials studying the treatment of Pulmonary Disease, Chronic Obstructive.
Investigational
Matched Iupac: … 1-(2-{[2-chloro-4-({[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}methyl)-5 …
VX-765
VX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase-1 (VRT-043198). VX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it blocks the hypersensitive response to an inflammatory stimulus.
Investigational
TP-252
TP-252 consists of magnesium L-lysinate bis-eicosapentaenoate, an ionizable salt of eicosapentaenoic acid (EPA), currently being investigated to treat familial adenomatous polyposis.
Investigational
Propacetamol
Propacetamol is a non-opioid analgesic devoid of the major contraindications. It is a derivative of acetaminophen, or paracetamol, with the molecular formula glycine, N, N-diethyl-,4-(acetylamino)phenyl ester. Propacetamol is a parenteral formulation of paracetamol and thus, it is a prodrug that is completely hydrolyzed to paracetamol. It is not available in...
Experimental
Midecamycin
Midecamycin is a naturally occurring 16-membered macrolide that fits under the category of acetoxy-substituted macrolide antibiotics. In this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on position 4 of the terminal sugar. Until 2017, midecamycin was still under the list of approved...
Experimental
ABT-341
ABT-341 is a potent and selective DPP-4 inhibitor with a structure very similar to sitagliptin (in 2D; the 3D structure is significantly different).
Experimental
Ecgonine
Experimental
Illicit
Matched Iupac: … (1R,2R,3S,5S)-3-hydroxy-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylic acid …
Methylecgonine
Experimental
Matched Iupac: … methyl (1R,2R,3S,5S)-3-hydroxy-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate …
NS-2359
NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression. Enhancing the function of the three neurotransmitters serotonin, noradrenalin and dopamine, NS2359 has a desired "triple-mode-of-action". This mode of action is expected to produce an optimal...
Investigational
Matched Iupac: … (1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane …
AG0301-COVID19
AG0301-COVID19 is a vaccine candidate developed by AnGes Inc. and Osaka University. The candidate is a plasmid DNA vaccine developed using an intradermal gene transfer method targeting the SARS-CoV-2 spike protein. The gene transfer method increases the efficiency of gene expression and antibody production capability, garnering a more efficient DNA...
Investigational
Matched Description: … On September 8, 2020 AnGes announced collaboration with Brickell Biotech, Inc. following completion of …
7,8-Dihydroneopterin
Experimental
Polaprezinc
Polaprezinc is a chelated form of zinc and L-carnosine. It is a zinc-related medicine approved for the first time in Japan, which has been clinically used to treat gastric ulcers [L1307, L1308]. It was determined that polaprezinc may be effective in pressure ulcer treatment . A study in 2013 showed...
Experimental
Loxicodegol
Loxicodegol was developed by Nektar Therapeutics as an opioid analgesic with low abuse potential for the treatment of chronic pain . The lack of abuse potential is believed to be due to the drug's slow rate of entry into brain, a unique characteristic compared to others in the opioid class...
Investigational
Displaying drugs 1501 - 1525 of 2084 in total